UroGen Pharma(US:URGN) Prnewswireยท2025-06-12 09:45Core Viewpoint - UroGen Pharma Ltd. is facing allegations related to misleading statements and study design issues concerning its lead pipeline product, UGN-102, during the class period from July 27, 2023, to May 15, 2025 [2]. Group 1: Allegations and Legal Context - The complaint alleges that the ENVISION clinical study was not adequately designed to demonstrate the effectiveness of UGN-102 due to the absence of a concurrent control arm [2]. - It is claimed that UroGen Pharma failed to address FDA warnings regarding the study design, leading to substantial risks regarding the approval of the New Drug Application (NDA) for UGN-102 [2]. - The allegations suggest that the company's positive statements about its business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased URGN shares during the specified class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for July 28, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].